Ionis (IONS) Beats On Q3 Earnings, Revenues Miss
Zacks Investment Research | Nov 06, 2017 09:07PM ET
Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Ionis has partnership agreements with several leading health care companies like Biogen (NASDAQ:BIIB) and GlaxoSmithKline among others.
In this quarter, the company received $270 million in upfront fees and milestone payments from its partners. Also, during the quarter the company submitted regulatory application for approval of volanesorsen in the United States and EU.
Ionis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average positive earnings surprise of 21.9%, having beaten estimates in two quarters and missed the same twice.
Currently, Ionis has a Zacks Rank #1 (Strong Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Ionis reported a breakeven earnings including stock based compensation which missed the Zacks Consensus Estimate of earnings of 2 cents. However, excluding stock based compensation the company reported earnings of 13 cents.
Revenues: Ionis posted revenues of $120.9 million, missing the consensus estimate of $129.48 million.
Key Stats: Research, development and patent expenses amounted to $80.2 million, down 5.2% year over year. General and administrative expenses increased almost 163% year over year to $26.8 million on increased costs related to commercialization of volanesorsen and inotersen, and increase in fees related to in-licensing of Spinraza. Spinraza saw strong uptake with $271 million in sales in this quarter, up 33.5% sequentially.
2017 Outlook: The company expects the operating expenses to increase sequentially in the fourth quarter due to costs related to launch of inotersen and volanesorsen.
Share Market Activity: Share price are down 0.02% in pre-market trading.
Ionis Pharmaceuticals, Inc. Price and EPS Surprise
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.